SCHEMBL29527921

SCHEMBL29527921

Cc1cc(C(=O)O)ccn1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 11/20 0.61
KDM5B Q9UGL1 6/20 0.61
KDM5C P41229 6/20 0.61
KDM5A P29375 6/20 0.61
KDM4A O75164 5/20 0.61
KDM4E B2RXH2 4/20 0.61
KDM2A Q9Y2K7 4/20 0.61
KDM3A Q9Y4C1 4/20 0.61
KDM6B O15054 3/20 0.61
TET3 O43151 1/20 0.61
BBOX1 O75936 1/20 0.61
ALDH1A1 P00352 1/20 0.61
MAPT P10636 1/20 0.61
ASPH Q12797 1/20 0.61
KDM4D Q6B0I6 1/20 0.61
TET2 Q6N021 1/20 0.61
ALKBH5 Q6P6C2 1/20 0.61
KDM7A Q6ZMT4 1/20 0.61
KDM8 Q8N371 1/20 0.61
TET1 Q8NFU7 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL353289 1.00 KDM4C (0.61) KDM4CKDM5BKDM5CKDM5AKDM4A
Hydrochloric Acid SCHEMBL1256781 0.98 KDM4C (0.59) KDM4CKDM5BKDM5CKDM5AKDM4A
Hydrochloric Acid SCHEMBL11077926 0.98 KDM4C (0.59) KDM4CKDM5BKDM5CKDM5AKDM4A
Tert-Butylamine SCHEMBL28094088 0.91 GABRP (0.55) KDM4CKDM5BKDM5CKDM5AKDM4A
SCHEMBL30083787 0.86 KDM4C (0.55) KDM4CKDM5BKDM5CKDM5AKDM4A
SCHEMBL28990167 0.85 CYP2C9 (0.54) KDM4CKDM5BKDM5CKDM5AKDM4A
SCHEMBL3356107 0.84 UHRF1 (0.50) KDM4CKDM5BKDM5CKDM5AKDM4A
Methyl Isonicotinate SCHEMBL30268553 0.83 KDM4E (0.63) KDM4CKDM5BKDM5CKDM5AKDM4A
SCHEMBL28472665 0.83 KDM5A (0.47) KDM4CKDM5BKDM5CKDM5AKDM4A
SCHEMBL363432 0.83 UHRF1 (0.48) KDM4CKDM5BKDM5CKDM5AKDM4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12152014-B2 Therapeutic compounds and compositions eXlthera Pharmaceuticals, Inc. (US) 2024-11-26 US disclosed
US-20240059670-A1 THERAPEUTIC COMPOUNDS AND COMPOSITIONS Cadrenal Therapeutics, Inc. 2024-02-22 US disclosed
US-20230348369-A1 NAMPT MODULATORS CYTOKINETICS, INC. 2023-11-02 US disclosed
US-11691962-B2 Therapeutic compounds and compositions EXITHERA PHARMACEUTICALS, INC. (US) 2023-07-04 US disclosed
US-20230133132-A1 NAMPT MODULATORS CYTOKINETICS, INC. 2023-05-04 US disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
EP-3983378-A1 INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY Praxis Biotech LLC (US) 2022-04-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240059670-A1 THERAPEUTIC COMPOUNDS AND COMPOSITIONS KLK5, KLK2, KLKB1 KDM4C 475/4885KDM5B 355/4885KDM5C 468/4885
US-12152014-B2 Therapeutic compounds and compositions KLK5, KLK2, KLKB1 KDM4C 475/4885KDM5B 355/4885KDM5C 468/4885
US-20230133132-A1 NAMPT MODULATORS NAMPT, MC4R, SIRT1 KDM4C 3730/4885KDM5B 3355/4885KDM5C 3980/4885
US-20230348369-A1 NAMPT MODULATORS NAMPT, NNT, NAPRT KDM4C 4071/4885KDM5B 3452/4885KDM5C 4291/4885
US-11691962-B2 Therapeutic compounds and compositions KLK5, KLK2, KLKB1 KDM4C 475/4885KDM5B 355/4885KDM5C 468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.